CStone Pharmaceuticals Company Description

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in China and internationally.

The company offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, a RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation.

Its product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma.

The company’s products also comprise CS1002, CS2009, CS2011, CS5007, CS5005, CS5008, CS5005-R, CS5006, and CS5009 for solid tumors; CS5001 for solid tumors and hematologic malignancies; and CS2013 and CS2015 for autoimmune diseases.

The company was incorporated in 2015 and is headquartered in Suzhou, China.

CStone Pharmaceuticals

Country	Cayman Islands
Founded	2015
Industry	Biotechnology
Sector	Healthcare
Employees	135
CEO	Jianxin Yang

Contact Details

Address: C1 Building Suzhou, 215123 China
Phone	86 512 8718 6550
Website	cstonepharma.com

Stock Details

Ticker Symbol	2616
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	KYG2588M1006
SIC Code	2836

Key Executives

Name	Position
Dr. Jianxin Yang M.D., Ph.D.	Chief Executive Officer, President of Research & Development and Executive Director
Weicong Ni	Chief Financial Officer and Joint Company Secretary
Ying Hua Zhang	Senior Vice President and Chief Operating Officer
Michael J. Choi M.B.A.	Chief Business and Strategy Officer
Dr. Yujuan La Ph.D.	Senior Vice President of Product Development
Dr. Qingmei Shi M.D., Ph.D.	Senior Vice President and Chief Medical Officer
Mei Yee Yung FCIS, FCS	Joint Company Secretary